Skip to main content

Peer Review reports

From: Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors

Original Submission
21 Mar 2017 Submitted Original manuscript
6 May 2017 Reviewed Reviewer Report - Sebastiano Buti
7 May 2017 Reviewed Reviewer Report - Won Kim
12 Jun 2017 Author responded Author comments - SYLVIE NEGRIER
Resubmission - Version 2
12 Jun 2017 Submitted Manuscript version 2
17 Jul 2017 Author responded Author comments - SYLVIE NEGRIER
Resubmission - Version 3
17 Jul 2017 Submitted Manuscript version 3
27 Jul 2017 Author responded Author comments - SYLVIE NEGRIER
Resubmission - Version 4
27 Jul 2017 Submitted Manuscript version 4
Publishing
1 Aug 2017 Editorially accepted
15 Aug 2017 Article published 10.1186/s12885-017-3527-7

You can find further information about peer review here.

Back to article page